# Inventiva H1 Results: Cash Runway and NATiV3 at Center

> Inventiva's cash runway and NATiV3 trial results drive investor focus after weak H1 earnings.
- Title: Inventiva H1 Results: Cash Runway and NATiV3 at Center
- Summary: Inventiva's cash runway and NATiV3 trial results drive investor focus after weak H1 earnings. Inventiva's cash runway extends to Q2 2027 with potential…
- Keywords: inventiva, iva, nativ3, cash runway, phase 3 trial, mash, lanifibranor, nasdaq, Results, Cash, Runway, Center
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/inventiva-iva-h1-results-put-cash-runway-and-nativ3-at-the-center-of-the-story
- Author: Newsdesk
- Published: 2026-09-29T18:29:22+00:00
- Read time: 1 min
- Topics: inventiva, iva, nativ3, cash runway, phase 3 trial, mash, lanifibranor, nasdaq
## Inventiva's H1 Results
Inventiva reported EUR 20,000 revenue for H1 2026, down from EUR 4.454 million in H1 2025.

> EUR 20,000
## R&D Expenses Rise
R&D expenses increased to EUR 46.238 million in H1 2026, reflecting NATiV3 trial progress.

> EUR 46.238 million
## Cash Position
Inventiva has EUR 166.1 million cash and EUR 67.8 million short-term deposits as of June 30, 2026.

> EUR 166.1 million
## Cash Runway Timeline
Base runway extends to end of Q2 2027, with potential extension to Q1 2028 if additional funding secured.

> Q2 2027
## NATiV3 Trial Status
Last patient completed final 72-week visit in NATiV3 on September 2, 2026.

> September 2, 2026
## Next Catalyst
NATiV3 topline results expected in Q4 2026, driving regulatory submission and potential 2028 launch.

> Q4 2026
## Key takeaway

Inventiva's cash runway extends to Q2 2027 with potential extension to Q1 2028 if additional funding is secured, pending NATiV3 trial results in Q4 2026.